Prescription medicine
Teriparatide Brand names: Forteo, Bonsity
Teriparatide (Forteo) is a prescription medicine with an FDA approval on record since 2002. FDA's NDC Directory lists it from 4 generic labelers, and pharmacies paid $479.95 per mL (Teriparatide 560 mcg/2.24 mL pen) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the teriparatide FDA label on DailyMed (effective August 3, 2026, Eli Lilly and Company); the NDA 21318 record on Drugs@FDA; every teriparatide label on DailyMed.
Highlights of the record
FDA label of August 3, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageFORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy.
Forms and strengths
Injection (solution); injection.
On the market
- Earliest approval on file
- November 26, 2002 Forteo, Lilly; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 3 first November 16, 2023; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 8 of which 4 under generic applications, 3 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $479.95 per mL Teriparatide 560 mcg/2.24 mL pen
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 0 since 2022 0 Class I among all firms' recalls; 1 more by firms not listed as its makers
- FAERS reports
- 112,087 through July 30, 2026
What is teriparatide used for?
From the label: indications and usageFORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. […]
Conditions named in the indications of teriparatide's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Parathyroid Hormone Analog.
Source: FDA drug label (Forteo), Eli Lilly and Company, effective August 3, 2026 (SPL set aae667c5-381f-4f92-93df-2ed6158d07b0), via openFDA; the full label on DailyMed
What does the patient leaflet for teriparatide say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about FORTEO?FORTEO may cause serious side effects, including: Allergic (hypersensitivity) reactions, including anaphylaxis. Stop using FORTEO and get medical help right away if you have any of the following symptoms of an allergic reaction: swelling of your face, lips, mouth, or tongue breathing problems fainting, dizziness, feeling lightheaded (low blood pressure) fast heartbeat itching rash hives Possible bone cancer. During drug testing, the medicine in FORTEO caused some rats to develop a bone cancer called osteosarcoma. Studies in people have not shown that FORTEO increases your chance of getting osteosarcoma. There is little information about the chance of getting osteosarcoma in patients using FORTEO beyond 2 years.
From the patient leaflet: How should I store FORTEO?Store FORTEO in the refrigerator between 36°F to 46°F (2°C to 8°C) until ready to use. Use FORTEO right away after you remove it from the refrigerator. Do not freeze FORTEO. Do not use FORTEO if it has been frozen. Throw away the FORTEO delivery device after 28 days even if it has medicine in it (see the User Manual). Do not use FORTEO after the expiration date printed on the delivery device and packaging. Recap FORTEO when not in use to protect it from physical damage and light. Keep FORTEO and all medicines out of the reach of children.
Source: FDA drug label (Forteo), Eli Lilly and Company, effective August 3, 2026 (SPL set aae667c5-381f-4f92-93df-2ed6158d07b0), via openFDA; the full label on DailyMed
Is there a generic for teriparatide (Forteo)?
The FDA approved the first generic teriparatide on November 16, 2023. 3 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists teriparatide from 4 labelers under a generic (ANDA) application and from 3 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2002 earliest approval on file
- 2023 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for teriparatide (Forteo)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $479.95 per mL (Teriparatide 560 mcg/2.24 mL pen), down 43% from $846.07 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Teriparatide 560 mcg/2.24 mL pen (generic)
- Forteo 560 mcg/2.24 mL pen injection (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Bonsity 560 mcg/2.24 mL pen | Generic | $479.95 per mL | $1,075.09 per pen | -43% |
| Teriparatide 560 mcg/2.24 mL pen | Generic | $479.95 per mL | $1,075.09 per pen | -43% |
| Forteo 560 mcg/2.24 mL pen injection | Brand | $1,841.27 per mL | $4,124.46 per pen | -0.4% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has teriparatide been recalled?
The FDA's Enforcement Report lists 1 recall naming teriparatide since 2022: 0 Class I (the most serious), 1 Class II, 0 Class III; 1 still ongoing. 1 of them is by a firm that FDA's NDC Directory does not list as a maker of teriparatide and that holds no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 7, 2022 | Class II | TMC Acquisition LLC dba Tailor Made Compounding not a listed maker | Lack of Assurance of Sterility |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the teriparatide label say about other medicines?
The teriparatide label names 2 other medicines in its interaction, contraindication or warning sections. The labels of 4 other medicines name teriparatide. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Digoxin | drug interactions | DRUG INTERACTIONS Digoxin: Transient hypercalcemia may predispose patients to digitalis toxicity |
| Warfarin | warnings and precautions | Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. |
Other labels that name teriparatide
Source: FDA drug label (Forteo), Eli Lilly and Company, effective August 3, 2026 (SPL set aae667c5-381f-4f92-93df-2ed6158d07b0), via openFDA; the full label on DailyMed
What do FAERS reports show for teriparatide?
The FDA Adverse Event Reporting System holds 112,087 reports that list teriparatide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 5,304 are coded as a death and 24,200 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as teriparatide?
2 other medicines are given the same way (subcutaneous) and in the same FDA class as teriparatide or labeled mainly for the same use (osteoporosis), the same class first. Osteoporosis lists all 16 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Denosumab | Osteoporosis | none listed | $1,862.74 per mL 60 mg/mL syringe | No current entry |
| Abaloparatide | Osteoporosis | none listed | n/a | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does teriparatide compare with medicines for the same use?
1 side-by-side page set teriparatide beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Other parathyroid hormone analogs
- the pharmacologic class, with prices and generics
- Teriparatide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other